Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
Company’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference’s scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company’s development-stage KRASG12C(ON) inhibitor, will each deliver a scientific presentation as part of the conference.
Details of Revolution Medicines’ participation in the 3rd Annual RAS-Targeted Drug Development Summit are as follows:
Presentations: | |
Title: | Targeting KRASG12C(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors |
Presenter: | Bob Nichols, Ph.D., project lead for RMC-6291 |
Date: | Wednesday, September 22, 2021 |
Time: | 11:55 a.m. Eastern |
Title: | Combination Strategies to Defeat RAS-Addicted Cancers |
Presenter: | Jan Smith, Ph.D., senior vice president, biology |
Date: | Wednesday, September 22, 2021 |
Time: | 2:00 p.m. Eastern |
Panel Discussion: | |
Title: | On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510 |
Moderator: | Steve Kelsey, M.D., president, research and development |
Date: | Thursday, September 23, 2021 |
Time: | 4:15 p.m. Eastern |
Scientific Track: | |
Title: | Validating Robust Combination Strategies |
Chairperson: | Steve Kelsey, M.D., president, research and development |
Date/Time: | Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern |
Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdevelopment.com/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.
Contacts:
For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401
sdiaz@vidasp.com
For Media:
Vida Strategic Partners
Tim Brons
415-675-7402
tbrons@vidasp.com
